Semaglutide vs Tirzepatide: Which One Is Right for You?
Semaglutide vs. Tirzepatide:
Which One Is Right for You?
Both medications can produce transformative weight loss results. But they work differently, they're dosed differently, and the data increasingly shows they're not interchangeable. Here's what the latest clinical evidence actually says.
How They Work
Both drugs belong to the GLP-1 class — they mimic natural hormones your body releases after eating, signaling fullness and slowing digestion. The difference is in how far each one goes.
A single-hormone agonist that targets GLP-1 receptors — the ones responsible for appetite suppression, slowed gastric emptying, and blood sugar regulation.
A dual-receptor agonist that hits both GLP-1 and GIP. That second hormone activates fat-burning pathways, enhances insulin response, and may amplify overall metabolic effects.
What the Data Shows
The landmark head-to-head trial (SURMOUNT-5, published in NEJM, May 2025) compared both medications directly in adults with obesity but without diabetes over 72 weeks. The results favored tirzepatide by a substantial margin.
at 72 weeks (SURMOUNT-5)
at 72 weeks (SURMOUNT-5)
Weight Loss Benchmarks
Across major clinical trials, tirzepatide consistently outperforms semaglutide on the thresholds that clinicians consider meaningful. The STEP 1 trial showed ~14.9% weight loss on semaglutide at 68 weeks; the SURMOUNT-1 trial showed ~20.9% on tirzepatide at 72 weeks.
A 2025 meta-analysis across seven studies totaling nearly 29,000 participants confirmed tirzepatide produced significantly greater weight loss, with a mean difference of roughly 4–5 kg in favor of tirzepatide. Real-world data mirrors these results: in ambulatory care settings, patients without diabetes on tirzepatide lost an average of 3.6 percentage points more body weight than those on semaglutide.
Side Effects
Both medications share a similar side effect profile — primarily gastrointestinal. Neither drug has a dramatically better safety record; the main difference is degree at higher doses.
In the SURMOUNT-5 trial, gastrointestinal adverse events were the most commonly reported for both groups. Tirzepatide may produce slightly more nausea at higher doses due to its dual-receptor mechanism, though this varies widely by individual and can often be managed with careful dose titration.
Dosing & Administration
Both medications are given as once-weekly subcutaneous injections. Dosing is started low and titrated upward over several months to help your body adjust and minimize side effects.
Target: 2.4 mg/week
Titration: ~16–20 weeks
Approved for: Adults & adolescents 12+
Target: 10–15 mg/week
Titration: ~12–20 weeks
Approved for: Adults
Cost & Coverage
Pricing has shifted meaningfully in recent years, and both manufacturers offer savings programs. Neither is inexpensive without insurance, but recent price reductions have made both more accessible. Coverage varies significantly depending on whether your diagnosis is type 2 diabetes or obesity — many plans cover the former but not the latter.
A 2025 cost-effectiveness analysis found injectable tirzepatide to be the most cost-effective option at a $150,000 per quality-adjusted life-year threshold, with a 98% probability of being cost-effective compared to alternatives — largely because of its stronger weight-loss outcomes per dollar spent at current pricing.
Always verify your specific plan's coverage before starting either medication. Our team at Defiance Health can help you navigate prior authorization and manufacturer savings programs.
The Bottom Line
There's no universal answer — but the evidence does give us useful direction.
Frequently Asked Questions
Yes, and many patients do. The transition requires a conversation with your provider about timing, dosing adjustments, and what to expect during the switch. Some patients who plateau on semaglutide see renewed weight loss after transitioning to tirzepatide.
Interestingly, one real-world study found that in patients with type 2 diabetes, the weight-loss gap between the two drugs narrowed — tirzepatide was not associated with significantly greater weight loss in that subgroup. The largest advantage for tirzepatide appears in people without diabetes.
Compounded formulations of both semaglutide and tirzepatide have been available through licensed compounding pharmacies during periods of shortage. These are not FDA-approved, carry different risk profiles, and should only be considered under the direct supervision of your prescribing provider. Availability changes frequently based on FDA guidance.
Ready to Find Out Which Medication Fits Your Goals?
Our providers at Defiance Health will review your health history, insurance coverage, and weight-loss objectives — and build a personalized plan for you.
Booking provided by Healthie
Based on current evidence, tirzepatide produces greater average weight loss. In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide resulted in 20.2% mean body weight reduction versus 13.7% for semaglutide over 72 weeks. That said, individual responses vary — some patients do exceptionally well on semaglutide, and clinical factors like insurance coverage, medical history, and tolerability all play a role in the decision.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results vary. Weight loss claims are based on clinical trial data and may not reflect typical patient outcomes.
Sources: SURMOUNT-5 (NEJM, 2025); PMC meta-analyses (PMC12263181, PMC12151102, PMC11970626); STEP 1 trial; SURMOUNT-1 trial; JMCP cost-effectiveness analysis (2025); real-world cohort studies.